Method of modulating TIGIT and PD-1 signalling pathways using 1,2,4-oxadiazole compounds
AssigneeAurigene Oncology Limited
InventorsPottayil Govindan Nair Sasikumar, Muralidhara Ramachandra, Seetharamaiah Setty Sudarshan Naremaddepalli, Chennakrishnareddy Gundala
Life of this patent
Estimating the term…
Abstract
The present invention relates to method of modulating TIGIT signaling pathway and PD-1 signaling pathway. The invention also encompasses the use of the compound of formula (I) or a stereoisomer thereof or a pharmaceutically acceptable salt thereof for the treatment of diseases or disorders mediated by both TIGIT signaling pathway and PD-1 signaling pathway.
Claims19
A method of modulating T cell immunoreceptor with Ig and ITIM domains (TIGIT) signaling pathway and programmed cell death 1 (PD-1) signaling pathway in a subject in need thereof, comprising administering to the subject Compound 19:
- or a stereoisomer thereof or a pharmaceutically acceptable salt thereof.
A method of treating a disease or disorder mediated by both TIGIT signalling pathway and PD-1 signalling pathway in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of Compound 19:
- or a stereoisomer thereof or a pharmaceutically acceptable salt thereof.
A method of modulating T cell immunoreceptor with Ig and ITIM domains (TIGIT) signaling pathway in a subject in need thereof, comprising administering to the subject Compound 19:
- or a stereoisomer thereof or a pharmaceutically acceptable salt thereof.
A method of treating a disease or disorder mediated by TIGIT signalling pathway in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of Compound 19:
- or a stereoisomer thereof or a pharmaceutically acceptable salt thereof.
Dependencies are inferred from the claim text.